Although it’s the fourth bellwether case in the multi-district litigation over the IVC devices, which are designed to prevent blood clots from passing through the body’s largest vein into the heart and lungs, Hyde v. Bard is the third case to make trial after its predecessor case was dismissed after the statute of limitations expired on the claims.
In the first case to go to trial, a federal jury in Phoenix found for plaintiff Sherr-Una Booker, awarding $3.6 million in damages. Bard prevailed in the second trial after the jury found that it properly warned of the potential complications and risks associated with the IVC filters. After the third bellwether was dismissed, Hyde v. Bard went to trial last month (earlier this week the judge hearing the case pared some of its claims).
Today, after a 12-day trial that ended Oct. 3, the jury found for Bard, Law 360 reported.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.